Kodiak Sciences KOD 深 沪
等待开盘 03-27 09:30:00 美东时间
39.76
+17.010
+74.77%
华盛通- 最 高40.4637
- 今 开35.41
- 成交量 1318.03万股
- 最 低 33.50
- 昨 收 22.75
- 总市值 24.56亿
- 52周最高 40.4637
- 市盈率 静 --
- 换手率 21.34%
- 52周最低 1.92
- 委 比 -97.88%
- 总股本 6175.85万
- 历史最高 171.21
- 量 比 13.44
- 振 幅 30.61%
- 历史最低 1.37
- 每 手 1
- 风险率 9.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings
U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings March 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Brown-Forman, Chord Energy and Olaplex Holdings on Friday. HIGHLIGHTS * Brown-Forman Corp BFb.N
今天 15:54
美股牛股 | 绩优股成避风港！AI软件股Navan暴涨43%；无人机公司Swarmer大涨逾15%
绩优股成避风港！AI软件股Navan暴涨43%、Precigen涨超25%；中东局势再生变数！无人机公司Swarmer隔夜大涨15%>>
11分钟前
Kodiak Sciences Stock Hits 52-Week High - Here's Why
Kodiak Sciences (KOD) hits new 52-week high, up 52% after Zenkuda trial success. Get the latest technical analysis, RSI, and support levels.
03-26 23:06
BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan
BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 26 (Reuters) - U.S. stock index futures pointed to a lower open on
03-26 21:26
Kodiak Reports Phase 3 Results For Zenkuda, Study Shows 85% Reduction In Sight-Threatening Complications With Zenkuda Treatment
Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced positive topline results
03-26 18:12
Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham
Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) versus sham in diabetic retinopathy. The primary
03-26 18:02
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $38 price target.
02-10 20:37
